Biodiagnostics company Glycominds Ltd. of Lod, Israel, maker of a blood test for detecting inflammatory bowel disease and the severity of Crohn's disease, announced this week it has joined the Biomolecular Photonic (BMP) Consortium. "Glycominds' glycan biomarker technology stands out as innovative and unique, providing the consortium with proven biomarkers for Crohn's disease and a great opportunity for diagnosing colorectal cancer," said Dr. Elisha Rabinovitz, the head of the BMP consortium and chief scientist for Given Imaging Ltd. BMP is a new, three-year consortium funded by the government of Israel to improve in vivo imaging diagnostics for Crohn's disease and colorectal cancer. The consortium has received $4 million in funding for its first year.